Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In silico</i> prediction and IgE serum screening for potential allergenicity of novel foods-a case of fungal biomass Fermotein®.

Frontiers in allergy·2026
Same author

Fel d 1-Expressing Plant-Derived Bioparticle: A Novel Treatment for Cat Allergy.

Allergy·2026
Same author

Frequency and severity of 192 foods causing food allergy in adults.

The journal of allergy and clinical immunology. Global·2026
Same author

The Evolution of Sesame Seed Allergy Over Time.

Allergy·2026
Same author

Food allergy outside the eight big foods in Europe: A systematic review and meta-analysis.

Clinical and translational allergy·2026
Same author

Molecular Allergen Diagnosis Reveals That Asthma Risk Is Linked to Desert Mugwort Pollen Exposure.

Allergy·2026

Related Experiment Video

Updated: Apr 20, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K

Birch pollen immunotherapy in mice: inhibition of Th2 inflammation is not sufficient to decrease airway

Leonie S van Rijt1, Lara Gouveia, Adrian Logiantara

  • 1Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.

International Archives of Allergy and Immunology
|November 22, 2014
PubMed
Summary

Subcutaneous immunotherapy (SCIT) for birch pollen (BP) allergy effectively reduces airway inflammation early on. However, significant improvement in airway hyper-responsiveness (AHR) requires sustained treatment, potentially linked to increased IgG2a antibody levels.

More Related Videos

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.3K

Related Experiment Videos

Last Updated: Apr 20, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

13.0K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.3K

Area of Science:

  • Immunology
  • Allergology
  • Respiratory Medicine

Background:

  • Subcutaneous immunotherapy (SCIT) aims to suppress allergic symptoms by reducing Th2 cytokine production.
  • Developing a reliable mouse model is crucial for understanding the mechanisms of birch pollen (BP) immunotherapy.

Purpose of the Study:

  • To establish a mouse model for BP SCIT to investigate mechanisms of clinical symptom improvement.
  • To evaluate the dose-dependent effects of BP extract (BPE) on allergic airway inflammation and airway hyper-responsiveness (AHR).

Main Methods:

  • Mice with BP-induced allergic airway inflammation received weekly SCIT with BPE adsorbed to alum.
  • Increasing doses of BPE were administered, and effects on airway inflammation and AHR were assessed after 2, 4, 6, or 8 injections.
  • Mice were rechallenged with BP allergen to evaluate all hallmarks of allergic asthma.

Main Results:

  • Immunotherapy suppressed IL-4, IL-5, IL-13, IL-10, and IFN-γ production, along with eosinophil recruitment and inflammation, after just two injections.
  • BP-specific immunoglobulins increased, but airway hyper-responsiveness (AHR) reduction required eight injections.
  • Reduced AHR correlated inversely with rising BP IgG2a antibody levels.

Conclusions:

  • BP SCIT rapidly suppresses Th2-mediated eosinophilic airway inflammation.
  • Significant reduction in AHR is achieved only after prolonged SCIT, likely due to the buildup of IgG2a antibody titers.
  • The study highlights the differential time course for suppressing inflammation versus AHR in BP allergy immunotherapy.